Sabra Health Care REIT Inc. Common Stock (SBRA)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Sabra as a healthcare landlord, not a fast grower. The filed record shows revenue rising from $236.2M in FY2023 to $284.6M in FY2024 and $356.9M in FY2025, and fiscal Q2 2026, ended 2026-06-30, revenue of $128.8M against $79.0M in fiscal Q2 2025. But the same fiscal Q2 2026 produced a net loss of $25.2M and diluted EPS of -$0.10, a sharp reversal from net income of $65.5M in fiscal Q2 2025. That makes the FairStock Lynch category TURNAROUND - returned to profit after a loss within the last three years - apt but fragile. FFO/AFFO, the correct REIT measures, are not in the data, so I lean on dividend yield, leverage, revenue trend, and price-to-book. At the 2026-10-13 close of $19.31, the dividend yield is 6.08%, price-to-book is 1.79, and TTM FCF is $371.6M, a 7.5% FCF yield. Those are not bad, but the debt-to-equity ratio of 0.96 and Altman Z-Score of 0.54 warn that the balance sheet deserves respect. The trailing P/E of 74.27 on EPS of $0.26 is distorted by depreciation and not the right lens for a REIT, yet EV/EBITDA of 18.70 and P/B of 1.79 do not scream bargain. Piotroski F-Score is 5/9. The moat, if any, is in healthcare real estate and leases, but the filed figures show no wide moat; tenant health matters. I see a modest, leveraged healthcare landlord with a high dividend, improving revenue, but inconsistent profit. The price looks fair, not compelling, until FFO/AFFO and consistent net income confirm the turnaround.

In plain English: Sabra Health Care REIT owns healthcare buildings in the United States and Canada and earns rent from them. The business looks mixed: revenue has been rising, but the latest reported quarter had a loss and the company carries a lot of debt. At $19.31, the price looks fair rather than clearly cheap compared with its accounting value and current earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer